Non-Small Cell Lung Cancer: Challenge and Improvement of Immune Drug Resistance
Lung cancer is the leading cause of cancer deaths in the world. At present, immunotherapy has made a great breakthrough in lung cancer treatment. A variety of immune checkpoint inhibitors have been applied into clinical practice, including antibodies targeting the programmed cell death-1, programmed...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.739191/full |
| _version_ | 1818667195988705280 |
|---|---|
| author | Fanming Kong Fanming Kong Ziwei Wang Ziwei Wang Dongying Liao Dongying Liao Jinhui Zuo Jinhui Zuo Hongxia Xie Hongxia Xie Xiaojiang Li Xiaojiang Li Yingjie Jia Yingjie Jia |
| author_facet | Fanming Kong Fanming Kong Ziwei Wang Ziwei Wang Dongying Liao Dongying Liao Jinhui Zuo Jinhui Zuo Hongxia Xie Hongxia Xie Xiaojiang Li Xiaojiang Li Yingjie Jia Yingjie Jia |
| author_sort | Fanming Kong |
| collection | DOAJ |
| description | Lung cancer is the leading cause of cancer deaths in the world. At present, immunotherapy has made a great breakthrough in lung cancer treatment. A variety of immune checkpoint inhibitors have been applied into clinical practice, including antibodies targeting the programmed cell death-1, programmed cell death-ligand 1, and cytotoxic T-lymphocyte antigen 4. However, in the actual clinical process, about 30%–50% of patients still do not receive long-term benefits. Abnormal antigen presentation, functional gene mutation, tumor microenvironment, and other factors can lead to primary or secondary resistance. In this paper, we reviewed the immune mechanism of immune checkpoint inhibitor resistance, various combination strategies, and prediction of biomarkers to overcome resistance in order to accurately screen out the advantageous population, expand the beneficiary population, and enable precise and individualized medicine. |
| first_indexed | 2024-12-17T06:16:34Z |
| format | Article |
| id | doaj.art-8b41b319fbc447fda91a0366fb29e4ce |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-17T06:16:34Z |
| publishDate | 2021-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-8b41b319fbc447fda91a0366fb29e4ce2022-12-21T22:00:29ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-08-011110.3389/fonc.2021.739191739191Non-Small Cell Lung Cancer: Challenge and Improvement of Immune Drug ResistanceFanming Kong0Fanming Kong1Ziwei Wang2Ziwei Wang3Dongying Liao4Dongying Liao5Jinhui Zuo6Jinhui Zuo7Hongxia Xie8Hongxia Xie9Xiaojiang Li10Xiaojiang Li11Yingjie Jia12Yingjie Jia13Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, ChinaNational Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, ChinaDepartment of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, ChinaNational Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, ChinaDepartment of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, ChinaNational Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, ChinaDepartment of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, ChinaNational Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, ChinaDepartment of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, ChinaNational Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, ChinaDepartment of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, ChinaNational Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, ChinaDepartment of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, ChinaNational Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, ChinaLung cancer is the leading cause of cancer deaths in the world. At present, immunotherapy has made a great breakthrough in lung cancer treatment. A variety of immune checkpoint inhibitors have been applied into clinical practice, including antibodies targeting the programmed cell death-1, programmed cell death-ligand 1, and cytotoxic T-lymphocyte antigen 4. However, in the actual clinical process, about 30%–50% of patients still do not receive long-term benefits. Abnormal antigen presentation, functional gene mutation, tumor microenvironment, and other factors can lead to primary or secondary resistance. In this paper, we reviewed the immune mechanism of immune checkpoint inhibitor resistance, various combination strategies, and prediction of biomarkers to overcome resistance in order to accurately screen out the advantageous population, expand the beneficiary population, and enable precise and individualized medicine.https://www.frontiersin.org/articles/10.3389/fonc.2021.739191/fullnon-small cell lung cancerimmunotherapydrug resistancestrategybiomarkers |
| spellingShingle | Fanming Kong Fanming Kong Ziwei Wang Ziwei Wang Dongying Liao Dongying Liao Jinhui Zuo Jinhui Zuo Hongxia Xie Hongxia Xie Xiaojiang Li Xiaojiang Li Yingjie Jia Yingjie Jia Non-Small Cell Lung Cancer: Challenge and Improvement of Immune Drug Resistance Frontiers in Oncology non-small cell lung cancer immunotherapy drug resistance strategy biomarkers |
| title | Non-Small Cell Lung Cancer: Challenge and Improvement of Immune Drug Resistance |
| title_full | Non-Small Cell Lung Cancer: Challenge and Improvement of Immune Drug Resistance |
| title_fullStr | Non-Small Cell Lung Cancer: Challenge and Improvement of Immune Drug Resistance |
| title_full_unstemmed | Non-Small Cell Lung Cancer: Challenge and Improvement of Immune Drug Resistance |
| title_short | Non-Small Cell Lung Cancer: Challenge and Improvement of Immune Drug Resistance |
| title_sort | non small cell lung cancer challenge and improvement of immune drug resistance |
| topic | non-small cell lung cancer immunotherapy drug resistance strategy biomarkers |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.739191/full |
| work_keys_str_mv | AT fanmingkong nonsmallcelllungcancerchallengeandimprovementofimmunedrugresistance AT fanmingkong nonsmallcelllungcancerchallengeandimprovementofimmunedrugresistance AT ziweiwang nonsmallcelllungcancerchallengeandimprovementofimmunedrugresistance AT ziweiwang nonsmallcelllungcancerchallengeandimprovementofimmunedrugresistance AT dongyingliao nonsmallcelllungcancerchallengeandimprovementofimmunedrugresistance AT dongyingliao nonsmallcelllungcancerchallengeandimprovementofimmunedrugresistance AT jinhuizuo nonsmallcelllungcancerchallengeandimprovementofimmunedrugresistance AT jinhuizuo nonsmallcelllungcancerchallengeandimprovementofimmunedrugresistance AT hongxiaxie nonsmallcelllungcancerchallengeandimprovementofimmunedrugresistance AT hongxiaxie nonsmallcelllungcancerchallengeandimprovementofimmunedrugresistance AT xiaojiangli nonsmallcelllungcancerchallengeandimprovementofimmunedrugresistance AT xiaojiangli nonsmallcelllungcancerchallengeandimprovementofimmunedrugresistance AT yingjiejia nonsmallcelllungcancerchallengeandimprovementofimmunedrugresistance AT yingjiejia nonsmallcelllungcancerchallengeandimprovementofimmunedrugresistance |